Stock VERSEON CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Verseon Corp London S.E.

Equities

USU9221J1098

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Verseon Gains US Patent Protection for Compounds That Could Eliminate Bleeding Risks of Current Anticoagulants
CI
Verseon Corporation Reports Earnings Results for the Half Year Ended June 30, 2019
CI
Verseon Corporation Reports Earnings Results for the Full Year Ended December 31, 2018
CI
Verseon Corporation Auditor Raises 'Going Concern' Doubt
CI
Verseon Showcases Candidates for Next-Generation Diabetic Eye Disease Drugs
CI
Verseon Corporation Presents Preclinical Efficacy Data for the First Development Candidate for Clinical Trials in Their Diabetic Eye Disease Program at ARVO 2019
CI
Verseon Corporation announced that it has received $0.1014 million in funding
CI
Verseon Corporation will Change its Ticker to VERS from VSN
CI
Verseon Corporation announced that it expects to receive $0.1014 million in funding
CI
Verseon Corporation Announces First Participants Receive Verseon PRrecision Oral AntiCoagulant in Phase I Trial
CI
Verseon Corporation Announces Resignation of Xavier Rolet as Non-Executive Director
CI
Verseon Corporation Announces Board Changes
CI
Verseon Corporation Unveils Transformative Blockchain Technology for Tokenized Securities
CI
Verseon Commences Phase I Trial for Precision Oral Anticoagulant VE-1902
CI
Verseon Corporation Provides Interim Report Charts Progress of Development Programs as it Submits Phase I Protocol for Precision Anticoagulant
CI
Verseon Corporation Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018
CI
Verseon Corporation Submits Phase I Protocol for VE-1902
CI
Verseon Corporation Announces Consolidated Earnings Results for the Year Ended December 31, 2018
CI
Verseon Preparing for Anticoagulant Phase I Trial
CI
Verseon Presents New Preclinical Data on Its Novel Class of Precision Oral Anticoagulants
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. Stock
  5. News Verseon Corp